Home » Stocks » GRTX

Galera Therapeutics, Inc. (GRTX)

Stock Price: $9.03 USD -0.28 (-3.01%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 235.12M
Revenue (ttm) n/a
Net Income (ttm) -74.52M
Shares Out 25.25M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $9.03
Previous Close $9.31
Change ($) -0.28
Change (%) -3.01%
Day's Open 9.30
Day's Range 9.02 - 9.47
Day's Volume 32,836
52-Week Range 5.87 - 15.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprie...

2 months ago - GlobeNewsWire

Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial

2 months ago - GlobeNewsWire

Describes mechanism which sensitizes cancer cells to radiotherapy

2 months ago - GlobeNewsWire

Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21

2 months ago - GlobeNewsWire

MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprie...

2 months ago - GlobeNewsWire

Galera Therapeutics (GRTX) stock is rocketing higher Thursday morning after providing an update on its pancreatic cancer clinical trial. The post GRTX Stock: The Big Cancer News That Has Galera Therapeu...

Other stocks mentioned: CHPT, NIO
2 months ago - InvestorPlace

Galera Therapeutics Inc (NASDAQ: GRTX) has announced updated results from its Phase 1/2 pilot trial evaluating GC4419 in patients with locally advanced pancreatic cancer (LAPC) who are undergoing stereo...

2 months ago - Benzinga

Near double the median overall survival observed in patients receiving Galera's dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential

2 months ago - GlobeNewsWire

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propr...

4 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

8 months ago - GlobeNewsWire

Presented Promising Interim Data from Placebo-controlled P ilot Dismutase Mimetic SBRT Combination Trial for P ancreatic C ancer

8 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, propri...

8 months ago - GlobeNewsWire

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting

8 months ago - GlobeNewsWire

Interim d ata on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures

9 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

10 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...

10 months ago - GlobeNewsWire

Galera Therapeutics is a promising company backed by prestigious venture firms.

10 months ago - Seeking Alpha

Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20

11 months ago - GlobeNewsWire

MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

11 months ago - GlobeNewsWire

Topline safety and efficacy data to be reported in the second half of 2020 Topline safety and efficacy data to be reported in the second half of 2020

1 year ago - GlobeNewsWire

Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program Retrospective analysis of patien...

1 year ago - GlobeNewsWire

ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19

1 year ago - GlobeNewsWire

MALVERN, Penn., April 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, p...

1 year ago - GlobeNewsWire

MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop...

1 year ago - GlobeNewsWire

-- Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer -- -- Marks expansion of lead product candidate avasopasem manganese ...

1 year ago - GlobeNewsWire

About GRTX

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 7, 2019
Stock Exchange
NASDAQ
Ticker Symbol
GRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GRTX stock is "Strong Buy." The 12-month stock price forecast is 20.75, which is an increase of 129.79% from the latest price.

Price Target
$20.75
(129.79% upside)
Analyst Consensus: Strong Buy